Acellular pertussis vaccine: Recommendations for use as the initial series in infants and children

N. A. Halsey, P. J. Chesney, M. A. Gerber, D. S. Gromisch, S. Kohl, S. M. Marcy, M. I. Marks, D. L. Murray, Jr Overall, L. K. Pickering, R. J. Whitley, R. Yogev, G. Peter, C. B. Hall, S. Hadler, R. Breiman, M. C. Hardegree, R. F. Jacobs, N. E. MacDonald, W. A. OrensteinN. R. Rabinovich, B. Schwartz

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

In 1991 and 1992, the US Food and Drug Administration approved two acellular pertussis vaccines combined with diphtheria and tetanus toxoids for use as the fourth and fifth doses after the initial three-dose primary series with the standard whole-cell pertussis vaccine administered at 2, 4, and 6 months of age. Recently completed trials of acellular pertussis vaccines conducted in Europe have documented the efficacy of these vaccines when administered as a primary series in infancy. Based on these studies, two acellular pertussis vaccines, Tripedia (Connaught Laboratories, Swiftwater, PA) and ACEL-IMUNE (Wyeth-Lederle Laboratories, Pearl River, NY), were licensed by the Food and Drug Administration for the initial three-dose series. Additional acellular pertussis vaccines are likely to be licensed for use in infants in the future. The recommendations in this statement supplement previous American Academy of Pediatrics guidelines for the use of acellular pertussis vaccines.

Original languageEnglish (US)
Pages (from-to)282-288
Number of pages7
JournalPediatrics
Volume99
Issue number2
DOIs
StatePublished - Feb 1 1997

Fingerprint

Acellular Vaccines
Pertussis Vaccine
Diphtheria-Tetanus-acellular Pertussis Vaccines
United States Food and Drug Administration
Diphtheria Toxoid
Tetanus Toxoid
Rivers
Vaccines
Guidelines
Pediatrics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Halsey, N. A., Chesney, P. J., Gerber, M. A., Gromisch, D. S., Kohl, S., Marcy, S. M., ... Schwartz, B. (1997). Acellular pertussis vaccine: Recommendations for use as the initial series in infants and children. Pediatrics, 99(2), 282-288. https://doi.org/10.1542/peds.99.2.282

Acellular pertussis vaccine : Recommendations for use as the initial series in infants and children. / Halsey, N. A.; Chesney, P. J.; Gerber, M. A.; Gromisch, D. S.; Kohl, S.; Marcy, S. M.; Marks, M. I.; Murray, D. L.; Overall, Jr; Pickering, L. K.; Whitley, R. J.; Yogev, R.; Peter, G.; Hall, C. B.; Hadler, S.; Breiman, R.; Hardegree, M. C.; Jacobs, R. F.; MacDonald, N. E.; Orenstein, W. A.; Rabinovich, N. R.; Schwartz, B.

In: Pediatrics, Vol. 99, No. 2, 01.02.1997, p. 282-288.

Research output: Contribution to journalReview article

Halsey, NA, Chesney, PJ, Gerber, MA, Gromisch, DS, Kohl, S, Marcy, SM, Marks, MI, Murray, DL, Overall, J, Pickering, LK, Whitley, RJ, Yogev, R, Peter, G, Hall, CB, Hadler, S, Breiman, R, Hardegree, MC, Jacobs, RF, MacDonald, NE, Orenstein, WA, Rabinovich, NR & Schwartz, B 1997, 'Acellular pertussis vaccine: Recommendations for use as the initial series in infants and children', Pediatrics, vol. 99, no. 2, pp. 282-288. https://doi.org/10.1542/peds.99.2.282
Halsey NA, Chesney PJ, Gerber MA, Gromisch DS, Kohl S, Marcy SM et al. Acellular pertussis vaccine: Recommendations for use as the initial series in infants and children. Pediatrics. 1997 Feb 1;99(2):282-288. https://doi.org/10.1542/peds.99.2.282
Halsey, N. A. ; Chesney, P. J. ; Gerber, M. A. ; Gromisch, D. S. ; Kohl, S. ; Marcy, S. M. ; Marks, M. I. ; Murray, D. L. ; Overall, Jr ; Pickering, L. K. ; Whitley, R. J. ; Yogev, R. ; Peter, G. ; Hall, C. B. ; Hadler, S. ; Breiman, R. ; Hardegree, M. C. ; Jacobs, R. F. ; MacDonald, N. E. ; Orenstein, W. A. ; Rabinovich, N. R. ; Schwartz, B. / Acellular pertussis vaccine : Recommendations for use as the initial series in infants and children. In: Pediatrics. 1997 ; Vol. 99, No. 2. pp. 282-288.
@article{bf52056ca222447587e19ae5ba7f1122,
title = "Acellular pertussis vaccine: Recommendations for use as the initial series in infants and children",
abstract = "In 1991 and 1992, the US Food and Drug Administration approved two acellular pertussis vaccines combined with diphtheria and tetanus toxoids for use as the fourth and fifth doses after the initial three-dose primary series with the standard whole-cell pertussis vaccine administered at 2, 4, and 6 months of age. Recently completed trials of acellular pertussis vaccines conducted in Europe have documented the efficacy of these vaccines when administered as a primary series in infancy. Based on these studies, two acellular pertussis vaccines, Tripedia (Connaught Laboratories, Swiftwater, PA) and ACEL-IMUNE (Wyeth-Lederle Laboratories, Pearl River, NY), were licensed by the Food and Drug Administration for the initial three-dose series. Additional acellular pertussis vaccines are likely to be licensed for use in infants in the future. The recommendations in this statement supplement previous American Academy of Pediatrics guidelines for the use of acellular pertussis vaccines.",
author = "Halsey, {N. A.} and Chesney, {P. J.} and Gerber, {M. A.} and Gromisch, {D. S.} and S. Kohl and Marcy, {S. M.} and Marks, {M. I.} and Murray, {D. L.} and Jr Overall and Pickering, {L. K.} and Whitley, {R. J.} and R. Yogev and G. Peter and Hall, {C. B.} and S. Hadler and R. Breiman and Hardegree, {M. C.} and Jacobs, {R. F.} and MacDonald, {N. E.} and Orenstein, {W. A.} and Rabinovich, {N. R.} and B. Schwartz",
year = "1997",
month = "2",
day = "1",
doi = "10.1542/peds.99.2.282",
language = "English (US)",
volume = "99",
pages = "282--288",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "2",

}

TY - JOUR

T1 - Acellular pertussis vaccine

T2 - Recommendations for use as the initial series in infants and children

AU - Halsey, N. A.

AU - Chesney, P. J.

AU - Gerber, M. A.

AU - Gromisch, D. S.

AU - Kohl, S.

AU - Marcy, S. M.

AU - Marks, M. I.

AU - Murray, D. L.

AU - Overall, Jr

AU - Pickering, L. K.

AU - Whitley, R. J.

AU - Yogev, R.

AU - Peter, G.

AU - Hall, C. B.

AU - Hadler, S.

AU - Breiman, R.

AU - Hardegree, M. C.

AU - Jacobs, R. F.

AU - MacDonald, N. E.

AU - Orenstein, W. A.

AU - Rabinovich, N. R.

AU - Schwartz, B.

PY - 1997/2/1

Y1 - 1997/2/1

N2 - In 1991 and 1992, the US Food and Drug Administration approved two acellular pertussis vaccines combined with diphtheria and tetanus toxoids for use as the fourth and fifth doses after the initial three-dose primary series with the standard whole-cell pertussis vaccine administered at 2, 4, and 6 months of age. Recently completed trials of acellular pertussis vaccines conducted in Europe have documented the efficacy of these vaccines when administered as a primary series in infancy. Based on these studies, two acellular pertussis vaccines, Tripedia (Connaught Laboratories, Swiftwater, PA) and ACEL-IMUNE (Wyeth-Lederle Laboratories, Pearl River, NY), were licensed by the Food and Drug Administration for the initial three-dose series. Additional acellular pertussis vaccines are likely to be licensed for use in infants in the future. The recommendations in this statement supplement previous American Academy of Pediatrics guidelines for the use of acellular pertussis vaccines.

AB - In 1991 and 1992, the US Food and Drug Administration approved two acellular pertussis vaccines combined with diphtheria and tetanus toxoids for use as the fourth and fifth doses after the initial three-dose primary series with the standard whole-cell pertussis vaccine administered at 2, 4, and 6 months of age. Recently completed trials of acellular pertussis vaccines conducted in Europe have documented the efficacy of these vaccines when administered as a primary series in infancy. Based on these studies, two acellular pertussis vaccines, Tripedia (Connaught Laboratories, Swiftwater, PA) and ACEL-IMUNE (Wyeth-Lederle Laboratories, Pearl River, NY), were licensed by the Food and Drug Administration for the initial three-dose series. Additional acellular pertussis vaccines are likely to be licensed for use in infants in the future. The recommendations in this statement supplement previous American Academy of Pediatrics guidelines for the use of acellular pertussis vaccines.

UR - http://www.scopus.com/inward/record.url?scp=0030994693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030994693&partnerID=8YFLogxK

U2 - 10.1542/peds.99.2.282

DO - 10.1542/peds.99.2.282

M3 - Review article

C2 - 9024463

AN - SCOPUS:0030994693

VL - 99

SP - 282

EP - 288

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 2

ER -